



ASX and Media Release  
2 December 2015

## **Circadian Receives \$3M R&D Tax Incentive**

**Melbourne, Australia** – Circadian Technologies Limited (ASX:CIR, OTCQX:CKDXY) has received an R&D tax incentive refund of \$3.042 million relating to expenditure in the financial year ended 30 June 2015.

The R&D tax refund relates to Australian and eligible overseas expenditure, mainly on the development of its lead molecule OPT-302.

Commenting on the refund, Circadian's CEO and MD, Dr Megan Baldwin said:

*"The receipt of \$3M significantly strengthens our balance sheet as we advance OPT-302 through a Phase 1/2A clinical trial for the treatment of wet AMD."*

### *Company & Media Enquiries:*

Megan Baldwin, PhD  
CEO & Managing Director  
Circadian Technologies Limited  
Tel: +61 (0) 3 9826 0399  
[Megan.baldwin@circadian.com.au](mailto:Megan.baldwin@circadian.com.au)

Rudi Michelson  
Monsoon Communications  
Tel: +61 (0) 3 9620 3333

*Join our email database to receive program updates:*

Tel: +61 (0) 3 9826 0399  
[info@circadian.com.au](mailto:info@circadian.com.au)  
[www.circadian.com.au](http://www.circadian.com.au)

## **About Circadian Technologies Limited**

Circadian (ASX:CIR; OTCQX:CKDXY) is a biologics drug developer focusing on ophthalmic disease therapies. It controls exclusive worldwide rights to a significant intellectual property portfolio around Vascular Endothelial Growth Factor (VEGF)-C, VEGF-D and VEGFR-3. The applications for the VEGF technology, which functions in regulating blood and lymphatic vessel growth, are substantial and broad. Circadian's internal product development programs are primarily focused on developing OPT-302 (formerly VGX-300, soluble VEGFR-3) for 'back of the eye' disease such as wet age-related macular degeneration (wet AMD).

## **Inherent risks of Investment in Biotechnology Companies**

There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialisation and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Circadian are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Thus investment in companies specialising in drug development must be regarded as highly speculative. Circadian strongly recommends that professional investment advice be sought prior to such investments.

## **Forward-looking statements**

Certain statements in this ASX announcement may contain forward-looking statements regarding Company business and the therapeutic and commercial potential of its technologies and products in development. Any statement describing Company goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the process of discovering, developing and commercialising drugs that can be proven to be safe and effective for use as human therapeutics, and in the endeavour of building a business around such products and services. Circadian undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Actual results could differ materially from those discussed in this ASX announcement.